Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$984M |
| 2 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$406M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$363M |
| 4 |
Comcast
CMCSA
|
+$305M |
| 5 |
DuPont de Nemours
DD
|
+$229M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.98B |
| 2 |
Linde
LIN
|
+$1.14B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$976M |
| 4 |
AGN
Allergan plc
AGN
|
+$735M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$469M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.7% |
| 2 | Financials | 4.92% |
| 3 | Consumer Discretionary | 4.46% |
| 4 | Healthcare | 4.33% |
| 5 | Communication Services | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
CALL
Murphy Oil
MUR
$4.78B
| $600K | ﹤0.01% |
43,500
-2,100
| -5% | -$24.1K |
|
3152
1st Source
SRCE
$2.12B
| $600K | ﹤0.01% |
16,897
+4,406
| +35% | +$146K |
|
3153
PUT
Trimble
TRMB
$13.9B
| $600K | ﹤0.01% |
13,900
-4,900
| -26% | -$184K |
|
|
POLY
3154
DELISTED
Plantronics, Inc.
POLY
| $600K | ﹤0.01% |
40,876
-193,779
| -83% | -$2.53M |
|
3155
Bally's
BALY
$658M
| $598K | ﹤0.01% |
26,839
+4,247
| +19% | +$74.9K |
|
3156
Abeona Therapeutics
ABEO
$413M
| $597K | ﹤0.01% |
8,184
+683
| +9% | +$47.2K |
|
3157
PUT
Pultegroup
PHM
$25.3B
| $596K | ﹤0.01% |
17,500
-2,800
| -14% | -$84.1K |
|
|
SPPI
3158
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $596K | ﹤0.01% |
176,196
+71,912
| +69% | +$210K |
|
3159
AngioDynamics
ANGO
$649M
| $595K | ﹤0.01% |
58,565
+6,927
| +13% | +$71.4K |
|
|
MXIM
3160
PUT
DELISTED
Maxim Integrated Products
MXIM
| $594K | ﹤0.01% |
9,800
-8,500
| -46% | -$473K |
|
|
EBIX
3161
DELISTED
Ebix Inc
EBIX
| $594K | ﹤0.01% |
26,570
-11,997
| -31% | -$247K |
|
3162
CALL
Bausch Health
BHC
$2.34B
| $593K | ﹤0.01% |
32,400
-319,700
| -91% | -$5.63M |
|
3163
ProShares Ultra Gold
UGL
$740M
| $593K | ﹤0.01% |
36,600
-21,880
| -37% | -$331K |
|
|
ZEN
3164
PUT
DELISTED
ZENDESK INC
ZEN
| $593K | ﹤0.01% |
6,700
-12,900
| -66% | -$993K |
|
|
ATNX
3165
DELISTED
Athenex, Inc. Common Stock
ATNX
| $592K | ﹤0.01% |
2,150
+636
| +42% | +$135K |
|
|
AHRT
3166
AH Realty Trust
AHRT
$517M
| $591K | ﹤0.01% |
59,339
-13,036
| -18% | -$118K |
|
3167
Diageo
DEO
$53.6B
| $591K | ﹤0.01% |
4,395
+1,429
| +48% | +$196K |
|
3168
Enova International
ENVA
$6.29B
| $591K | ﹤0.01% |
39,746
-11,266
| -22% | -$157K |
|
3169
Sonoco
SON
$5.74B
| $591K | ﹤0.01% |
11,324
+9,715
| +604% | +$481K |
|
3170
Ascendis Pharma A/S
ASND
$16.8B
| $589K | ﹤0.01% |
3,983
+3,654
| +1,111% | +$502K |
|
3171
CALL
Baker Hughes
BKR
$61.1B
| $589K | ﹤0.01% |
38,300
-32,600
| -46% | -$477K |
|
3172
CTS Corp
CTS
$1.89B
| $589K | ﹤0.01% |
29,408
+2,477
| +9% | +$53.1K |
|
3173
TriMas Corp
TRS
$1.44B
| $589K | ﹤0.01% |
24,558
+9,661
| +65% | +$222K |
|
|
AXNX
3174
DELISTED
Axonics, Inc. Common Stock
AXNX
| $588K | ﹤0.01% |
16,778
+10,609
| +172% | +$365K |
|
3175
Malibu Boats
MBUU
$567M
| $586K | ﹤0.01% |
11,300
+4,382
| +63% | +$175K |
|
Similar funds
Barclays's Q2 2020 Portfolio in Review
As of Q2 2020, Barclays held 6,627 positions worth $129B, up 2.3% from $127B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Barclays withdrew a net $22.7B in Q2 2020, closing 960 positions and reducing 2,655 holdings. Its most notable exit was Allergan plc, an estimated $735M position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, up from 8.3% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares MSCI ACWI ex US ETF worth $123M.
- Barclays's largest Q2 2020 buy was iShares MSCI ACWI ex US ETF: 2,853,067 shares worth $123M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q2 2020, an estimated $984M increase.
- Barclays's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.98B.
- Barclays fully exited Allergan plc in Q2 2020, selling an estimated $735M.
- Barclays's ten largest holdings make up 34% of its $129B portfolio in Q2 2020.
- Barclays opened 468 new positions and closed 960 in Q2 2020.
- Barclays's portfolio value rose 2.3% quarter-over-quarter to $129B.
Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.